Our top pick for
PPD, Inc is a drug manufacturers—specialty & generic business based in the US. PPD shares (PPD) are listed on the NASDAQ and all prices are listed in US Dollars. PPD employs 24,000 staff and has a trailing 12-month revenue of around USD$4.2 billion.
Since the stock market crash in March caused by coronavirus, PPD's share price has had significant positive movement.
Its last market close was USD$36.5, which is 15.40% up on its pre-crash value of USD$30.88 and 244.02% up on the lowest point reached during the March crash when the shares fell as low as USD$10.61.
If you had bought USD$1,000 worth of PPD shares at the start of February 2020, those shares would have been worth USD$inf at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$inf.
|Latest market close||USD$36.5|
|52-week range||USD$10.61 - USD$37.51|
|50-day moving average||USD$34.9091|
|200-day moving average||USD$29.4354|
|Wall St. target price||USD$38.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.09|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-10-12)||-0.60%|
|1 month (2020-09-22)||3.31%|
|3 months (2020-07-20)||20.82%|
|6 months (2020-04-20)||59.60%|
|1 year (2019-10-18)||N/A|
|2 years (2018-10-18)||N/A|
|3 years (2017-10-18)||N/A|
|5 years (2015-10-18)||N/A|
Valuing PPD stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PPD's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PPD's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 450x. In other words, PPD shares trade at around 450x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PPD's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7114. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PPD's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PPD's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$702.8 million.
The EBITDA is a measure of a PPD's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.2 billion|
|Operating margin TTM||10.44%|
|Gross profit TTM||USD$2.5 billion|
|Return on assets TTM||4.74%|
|Return on equity TTM||0%|
|Market capitalisation||USD$13.4 billion|
TTM: trailing 12 months
There are currently 1.8 million PPD shares held short by investors – that's known as PPD's "short interest". This figure is 22.7% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting PPD shares can be evaluated.
PPD's "short interest ratio" (SIR) is the quantity of PPD shares currently shorted divided by the average quantity of PPD shares traded daily (recently around 2.6 million). PPD's SIR currently stands at 0.69. In other words for every 100,000 PPD shares traded daily on the market, roughly 690 shares are currently held short.
However PPD's short interest can also be evaluated against the total number of PPD shares, or, against the total number of tradable PPD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PPD's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 PPD shares in existence, roughly 10 shares are currently held short) or 0.015% of the tradable shares (for every 100,000 tradable PPD shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PPD.
Find out more about how you can short PPD stock.
We're not expecting PPD to pay a dividend over the next 12 months.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
Steps to owning and managing MHO, with 24-hour and historical pricing before you buy.
Steps to owning and managing HLIT, with 24-hour and historical pricing before you buy.
Steps to owning and managing XELA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PDD, with 24-hour and historical pricing before you buy.
Steps to owning and managing JAKK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IMMU, with 24-hour and historical pricing before you buy.
Steps to owning and managing PRCP, with 24-hour and historical pricing before you buy.
Steps to owning and managing MNRO, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMRX, with 24-hour and historical pricing before you buy.
Steps to owning and managing YUM, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.